AIMS: This study aimed to determine the relative effectiveness of 12 months of interim methadone (IM; supervised methadone with emergency counseling only for the first 4 months of treatment), standard methadone treatment (SM; with routine counseling) and restored methadone treatment (RM: routine counseling with smaller case-loads). DESIGN: A randomized controlled trial was conducted comparing IM, SM and RM treatment. IM lasted for 4 months, after which participants were transferred to SM. SETTING: The study was conducted in two methadone treatment programs in Baltimore, MD, USA. PARTICIPANTS: The study included 230 adult methadone patients newly admitted through waiting-lists. MEASUREMENTS: We administered the Addiction Severity Index and a supplemental questionnaire at baseline, 4 and 12 months post- baseline. Measurements included retention in treatment, self-reported days of heroin and cocaine use, criminal behavior and arrests and urine tests for heroin and cocaine metabolites. FINDINGS: At 12 months, on an intent-to-treat basis, there were no significant differences in retention in treatment among the IM, SM and RM groups (60.6%, 54.8% and 37.0%, respectively). Positive urine tests for the three groups declined significantly from baseline (Ps < 0.001 and 0.003, for heroin and cocaine metabolites, respectively) but there were no significant group x time interactions for these measures. At least one arrest was reported by 30.6% of the sample during the year, but there were no significant between-group effects. CONCLUSIONS: Limited availability of drug counseling services should not be a barrier to providing supervised methadone to adults dependent on heroin--at least for the first 4 months of treatment.
RCT Entities:
AIMS: This study aimed to determine the relative effectiveness of 12 months of interim methadone (IM; supervised methadone with emergency counseling only for the first 4 months of treatment), standard methadone treatment (SM; with routine counseling) and restored methadone treatment (RM: routine counseling with smaller case-loads). DESIGN: A randomized controlled trial was conducted comparing IM, SM and RM treatment. IM lasted for 4 months, after which participants were transferred to SM. SETTING: The study was conducted in two methadone treatment programs in Baltimore, MD, USA. PARTICIPANTS: The study included 230 adult methadonepatients newly admitted through waiting-lists. MEASUREMENTS: We administered the Addiction Severity Index and a supplemental questionnaire at baseline, 4 and 12 months post- baseline. Measurements included retention in treatment, self-reported days of heroin and cocaine use, criminal behavior and arrests and urine tests for heroin and cocaine metabolites. FINDINGS: At 12 months, on an intent-to-treat basis, there were no significant differences in retention in treatment among the IM, SM and RM groups (60.6%, 54.8% and 37.0%, respectively). Positive urine tests for the three groups declined significantly from baseline (Ps < 0.001 and 0.003, for heroin and cocaine metabolites, respectively) but there were no significant group x time interactions for these measures. At least one arrest was reported by 30.6% of the sample during the year, but there were no significant between-group effects. CONCLUSIONS: Limited availability of drug counseling services should not be a barrier to providing supervised methadone to adults dependent on heroin--at least for the first 4 months of treatment.
Authors: Robert P Schwartz; Jerome H Jaffe; David A Highfield; Jason M Callaman; Kevin E O'Grady Journal: Drug Alcohol Depend Date: 2006-06-21 Impact factor: 4.492
Authors: Dennis McCarty; Nancy A Perrin; Carla A Green; Michael R Polen; Michael C Leo; Frances Lynch Journal: Drug Alcohol Depend Date: 2010-10-01 Impact factor: 4.492
Authors: Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes Journal: Arch Gen Psychiatry Date: 2006-01
Authors: Nancy M Petry; John M Roll; Bruce J Rounsaville; Samuel A Ball; Maxine Stitzer; Jessica M Peirce; Jack Blaine; Kimberly C Kirby; Dennis McCarty; Kathleen M Carroll Journal: J Consult Clin Psychol Date: 2008-12
Authors: Shannon Gwin Mitchell; Jan Gryczynski; Sharon M Kelly; Kevin E O'Grady; Jerome H Jaffe; Yngvild K Olsen; Robert P Schwartz Journal: J Drug Issues Date: 2014-01
Authors: Robert P Schwartz; Sharon M Kelly; Shannon G Mitchell; Jan Gryczynski; Kevin E O'Grady; Devang Gandhi; Yngvild Olsen; Jerome H Jaffe Journal: Addiction Date: 2016-11-10 Impact factor: 6.526
Authors: Sharon M Kelly; Kevin E Oʼgrady; Jerome H Jaffe; Devang Gandhi; Robert P Schwartz Journal: J Addict Med Date: 2013 Mar-Apr Impact factor: 3.702
Authors: Robert P Schwartz; Pierre K Alexandre; Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Jerome H Jaffe Journal: J Subst Abuse Treat Date: 2013-10-14